Page last updated: 2024-11-12

pp-33

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9995375
CHEMBL ID89081
SCHEMBL ID2820118
MeSH IDM0270169

Synonyms (12)

Synonym
CHEMBL89081 ,
2-(2,6-diisopropyl-phenyl)-isoindole-1,3-dione
2-(2,6-diisopropylphenyl)isoindoline-1,3-dione
bdbm50075329
57169-26-3
RPANGAGEVTXEQR-UHFFFAOYSA-N
n-(2,6-diisopropylphenyl)-phthalimide
n-(2.6-diisopropylphenyl)-phthalimide
SCHEMBL2820118
DTXSID00433915
2-[2,6-di(propan-2-yl)phenyl]isoindole-1,3-dione
pp33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)325.30000.00010.444410.0000AID56226
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID293618Cytotoxicity against Vero cells2007European journal of medicinal chemistry, May, Volume: 42, Issue:5
Novel and versatile methodology for synthesis of cyclic imides and evaluation of their cytotoxic, DNA binding, apoptotic inducing activities and molecular modeling study.
AID252970Percent cell proliferation of human leukemia cell line HL-60 at 1*E-5 M2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Cell differentiation inducers derived from thalidomide.
AID293621Apoptotic activity in human blood neutrophils after 72 hrs2007European journal of medicinal chemistry, May, Volume: 42, Issue:5
Novel and versatile methodology for synthesis of cyclic imides and evaluation of their cytotoxic, DNA binding, apoptotic inducing activities and molecular modeling study.
AID251888Cell growth-inhibitory activity toward human leukemia cell line HL60 at 6 uM concentration2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Tubulin-polymerization inhibitors derived from thalidomide.
AID56226Inhibitory activity against Dipeptidylpeptidase IV (DPP IV) in human acute lymphoblastic leukemia MOLT-4 cell line1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.
AID251887Cell growth-inhibitory activity toward human leukemia cell line HL60 at 3 uM concentration2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Tubulin-polymerization inhibitors derived from thalidomide.
AID257636Inhibitory activity in HUVEC tube formation assay at 100 uM2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Angiogenesis inhibitors derived from thalidomide.
AID293622Partition coefficient, log P of the compound2007European journal of medicinal chemistry, May, Volume: 42, Issue:5
Novel and versatile methodology for synthesis of cyclic imides and evaluation of their cytotoxic, DNA binding, apoptotic inducing activities and molecular modeling study.
AID81275Tumor necrosis factor-alpha production in human leukemia cell line (HL-60) stimulated with 10 nM 12-O-tetradecanoylphorbol 13-acetate (TPA) at 30 uMolar.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity.
AID38364Inhibitory activity against aminopeptidase N (APN) in human acute lymphoblastic leukemia MOLT-4 cell line1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.
AID309667Inhibition of IL-1-alpha-induced NF-kappaB activation in HeLa cells assessed as blocking of p50/p65 nuclear translocation2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Inhibitors of NF-kappaB derived from thalidomide.
AID293620Apoptotic activity in human blood neutrophils after 48 hrs2007European journal of medicinal chemistry, May, Volume: 42, Issue:5
Novel and versatile methodology for synthesis of cyclic imides and evaluation of their cytotoxic, DNA binding, apoptotic inducing activities and molecular modeling study.
AID293619Apoptotic activity in human blood neutrophils after 24 hrs2007European journal of medicinal chemistry, May, Volume: 42, Issue:5
Novel and versatile methodology for synthesis of cyclic imides and evaluation of their cytotoxic, DNA binding, apoptotic inducing activities and molecular modeling study.
AID218272In vitro cytotoxicity against human embryonic lung fibroblast WI-38 cells.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity.
AID257637Inhibitory activity in HUVEC tube formation assay at 30 uM2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Angiogenesis inhibitors derived from thalidomide.
AID38377Inhibitory activity against aminopeptidase N assayed by the L-Ala-MCA method.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton.
AID219416Cytotoxicity in human embryonic lung flbroblast Wl-38 cells using WST-1 viability assay1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
Nonpeptide small-molecular inhibitors of dipeptidyl peptidase IV: N-phenylphthalimide analogs.
AID251661Inhibitory activity against tubulin polymerization at 20 uM2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Tubulin-polymerization inhibitors derived from thalidomide.
AID1057531Antiproliferative activity against human DU145 cells assessed as growth inhibition by MTS assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-activity relationship studies of thalidomide analogs with a taxol-like mode of action.
AID257638Inhibitory activity in HUVEC tube formation assay at 10 uM2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Angiogenesis inhibitors derived from thalidomide.
AID270729Inhibition of tubulin polymerization in porcine brain at 20 uM2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide.
AID252627NBT positivity against human leukemia cell line HL-60 at 1*E-5 M2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Cell differentiation inducers derived from thalidomide.
AID1057532Antiproliferative activity against human PC3 cells assessed as growth inhibition by MTS assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-activity relationship studies of thalidomide analogs with a taxol-like mode of action.
AID81272Tumor necrosis factor-alpha production in human leukemia cell line (HL-60) stimulated with 50 nM okadaic acid (OA), at 30 uMolar.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity.
AID251886Cell growth-inhibitory activity toward human leukemia cell line HL60 at 10 uM concentration2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Tubulin-polymerization inhibitors derived from thalidomide.
AID1057530Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition by MTS assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-activity relationship studies of thalidomide analogs with a taxol-like mode of action.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (30.00)18.2507
2000's6 (60.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.64 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index64.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]